Pacira BioSciences, Inc. (PCRX) stock
PCRXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 6/3028% above fair value
$36.48+0.00 (0.00%)
Close on Nov 17, 2026Market cap $1.45BP/E 104.2Yield –
Pacira BioSciences total assets
Total assets on the balance sheet at the end of each period.
Pacira BioSciences's total assets was $1.24B at Jun 30, 2026. For fiscal 2025 it was $1.26B, down 18.6% from the year before. Over ten years it grew 12.6% a year on average. The highest annual figure on record is $2.08B in fiscal 2021.
Annual total assets
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.26B | -18.6% |
| FY2024 | Dec 31, 2024 | $1.55B | -1.3% |
| FY2023 | Dec 31, 2023 | $1.57B | -6.4% |
| FY2022 | Dec 31, 2022 | $1.68B | -19.0% |
| FY2021 | Dec 31, 2021 | $2.08B | +62.8% |
| FY2020 | Dec 31, 2020 | $1.27B | +53.4% |
| FY2019 | Dec 31, 2019 | $831.07M | +20.6% |
| FY2018 | Dec 31, 2018 | $689.35M | +9.7% |
| FY2017 | Dec 31, 2017 | $628.37M | +60.5% |
| FY2016 | Dec 31, 2016 | $391.47M | +1.0% |
| FY2015 | Dec 31, 2015 | $387.74M | +18.9% |
| FY2014 | Dec 31, 2014 | $326.07M | +92.0% |
| FY2013 | Dec 31, 2013 | $169.82M | +51.6% |
| FY2012 | Dec 31, 2012 | $112.05M | -1.3% |
| FY2011 | Dec 31, 2011 | $113.49M | +70.5% |
| FY2010 | Dec 31, 2010 | $66.56M | – |
Quarterly total assets
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $1.24B | -19.1% |
| Q1 FY2026 | Mar 31, 2026 | $1.21B | -23.8% |
| Q4 FY2025 | Dec 31, 2025 | $1.26B | -18.6% |
| Q3 FY2025 | Sep 30, 2025 | $1.30B | -14.7% |
| Q2 FY2025 | Jun 30, 2025 | $1.54B | -6.7% |
| Q1 FY2025 | Mar 31, 2025 | $1.59B | +0.2% |
| Q4 FY2024 | Dec 31, 2024 | $1.55B | -1.3% |
| Q3 FY2024 | Sep 30, 2024 | $1.52B | -0.8% |
| Q2 FY2024 | Jun 30, 2024 | $1.65B | +6.8% |
| Q1 FY2024 | Mar 31, 2024 | $1.58B | +3.9% |
| Q4 FY2023 | Dec 31, 2023 | $1.57B | -6.4% |
| Q3 FY2023 | Sep 30, 2023 | $1.53B | -11.5% |
| Q2 FY2023 | Jun 30, 2023 | $1.54B | -11.1% |
| Q1 FY2023 | Mar 31, 2023 | $1.52B | -19.5% |
| Q4 FY2022 | Dec 31, 2022 | $1.68B | -19.0% |
| Q3 FY2022 | Sep 30, 2022 | $1.73B | +27.9% |
| Q2 FY2022 | Jun 30, 2022 | $1.73B | +30.8% |
| Q1 FY2022 | Mar 31, 2022 | $1.89B | +46.9% |
| Q4 FY2021 | Dec 31, 2021 | $2.08B | +62.8% |
| Q3 FY2021 | Sep 30, 2021 | $1.36B | +11.1% |
| Q2 FY2021 | Jun 30, 2021 | $1.33B | +53.1% |
| Q1 FY2021 | Mar 31, 2021 | $1.29B | +56.8% |
| Q4 FY2020 | Dec 31, 2020 | $1.27B | +53.4% |
| Q3 FY2020 | Sep 30, 2020 | $1.22B | +51.1% |
| Q2 FY2020 | Jun 30, 2020 | $866.11M | +9.9% |
| Q1 FY2020 | Mar 31, 2020 | $821.38M | +14.2% |
| Q4 FY2019 | Dec 31, 2019 | $831.07M | +20.6% |
| Q3 FY2019 | Sep 30, 2019 | $807.49M | +22.5% |
| Q2 FY2019 | Jun 30, 2019 | $787.84M | +22.6% |
| Q1 FY2019 | Mar 31, 2019 | $719.16M | +15.6% |
| Q4 FY2018 | Dec 31, 2018 | $689.35M | +9.7% |
| Q3 FY2018 | Sep 30, 2018 | $659.05M | +8.7% |
| Q2 FY2018 | Jun 30, 2018 | $642.68M | +6.1% |
| Q1 FY2018 | Mar 31, 2018 | $622.04M | +3.7% |
| Q4 FY2017 | Dec 31, 2017 | $628.37M | +60.5% |
| Q3 FY2017 | Sep 30, 2017 | $606.09M | +59.0% |
| Q2 FY2017 | Jun 30, 2017 | $605.75M | – |
| Q1 FY2017 | Mar 31, 2017 | $599.96M | – |
| Q4 FY2016 | Dec 31, 2016 | $391.47M | – |
| Q3 FY2016 | Sep 30, 2016 | $381.15M | – |
See a number that looks wrong?